Liquid biopsy is a non-invasive diagnostic technique that analyses biological fluids, primarily blood, to detect and monitor diseases, particularly cancer. Unlike traditional tissue biopsies, which require surgical removal of a tissue sample, liquid biopsy examines circulating tumour cells (CTCs), cell-free DNA (cfDNA), or other biomarkers shed by tumours into the bloodstream. This method allows for real-time monitoring of disease progression, detection of genetic mutations, and assessment of treatment response. Liquid biopsy techniques include next-generation sequencing, polymerase chain reaction (PCR), and other molecular analysis methods. By providing detailed molecular insights without the need for invasive procedures, liquid biopsy is increasingly used in oncology research, early cancer detection, and personalised medicine strategies.
According to SPER market research, ‘Middle East Liquid Biopsy Market Size- By Technology, By Work Flow, By Usage, By Sample, By Circulating Biomarker, By Product- Regional Outlook, Competitive Strategies and Segment Forecast to 2033’ states that the Middle East Liquid Biopsy Market is estimated to reach USD 0.208 billion by 2033 with a CAGR of 13.89%.
Drivers:
The process of liquid biopsies involves separating tumour-derived materials from cancer patients’ bodily fluids, such as circulating tumour cells, circulating tumour DNA, and tumour extracellular vesicles, among others, and then analysing the genomic and proteomic information found there. According to the review, techniques for isolating and analysing liquid biopsies have advanced quickly in recent years, offering more information about tumour features like mutations, tumour staging, tumour progression, heterogeneity, and gene and clonal evolution, among other things. Precision medicine-based cancer treatment, ongoing monitoring, and the identification of therapeutic resistance markers have all been made possible by liquid biopsies taken from cancer patients. The demand for non-invasive cancer diagnostic techniques is rising because they provide a safer and more patient-friendly approach.
Download Free Sample Detailed Report – https://www.sperresearch.com/report-store/middle-east-liquid-biopsy-market.aspx?sample=1
Restraints:
Although the liquid biopsy shows promise for non-invasive disease monitoring and detection, it faces many obstacles, chief among them being its high expense. Its widespread adoption is hampered by the cost of specialised equipment, such as automated sample processing systems, digital PCR machines, and NGS platforms. The initial investment and continuing maintenance costs may be prohibitive for smaller healthcare facilities, which restricts their capacity to provide these tests to patients. The potential of liquid biopsy tests for cancer detection, monitoring, and individualised treatment plans has led to an increase in demand for them; however, the implementation of liquid biopsy programs may be hampered by a lack of funding, personnel, and equipment. As a result, there is frequently a shortage of qualified personnel who can perform these tests, especially in areas with limited resources or in medical settings.
South Africa dominates the Middle East and Africa liquid biopsy market. This is due to its advanced healthcare infrastructure and growing adoption of non-invasive diagnostic technologies for early cancer detection and personalised treatment. Some of the key market players are: Bio-Rad Laboratories, Inc., Bioscience Institute S.p.A., Eurofins Scientific, F. Hoffmann-La Roche Ltd, Guardant Health, Illumina, Inc., and Natera, Inc.
For More Information, refer to below link: –
Middle East Liquid Biopsy Market Size
Related Reports:
Breast Cancer Core Needle Biopsy Market
Follow Us –
LinkedIn | Instagram | Facebook | Twitter
Contact Us:
Sara Lopes, Business Consultant — USA
SPER Market Research
enquiries@sperresearch.com
+1–347–460–2899